

BIBLIOGRAFÍA Ojo de Markov nº 28:

Antiagregación en prevención primaria ¿en qué pacientes es beneficiosa?

1. U.S. Food and Drug Administration (FDA) Protecting and Promoting **Your** Health. Use of Aspirin for Primary Prevention of Heart Attack and Stroke (05/02/2014). Disponible en: <http://www.fda.gov/drugs/resourcesforyou/consumers/ucm390574.htm#secondary>
2. U.S. Food and Drug Administration (FDA). Regulations.gov. Citizen Petition Denial Response from FDA to Bayer (Mayo/20149 Healthcare, LLC. Disponible en: <http://www.regulations.gov/#!documentDetail;D=FDA-1977-N-0018-0101>
3. Position Statement. Standards of Medical Care in Diabetes. 2007 Diabetes Care. 30; suplemento 1:S4-S41. Disponible en: <http://care.diabetesjournals.org/>
4. U.S. Preventive Services Task Force. Aspirin for the Prevention of Cardiovascular Disease: U.S. Preventive Services Task Force Recommendation Statement. Ann Intern Med. 2009;150: 396-404.
5. ADA Position Statement. Aspirin for primary prevention of cardiovascular events in people with diabetes. A position statement of the American Diabetes association, a scientific statement of the American Heart Association, and an expert consensus document of the American College of Cardiology Foundation. Diabetes Care. 2010. Nº 6. 33:1395-1402. Disponible en: <http://care.diabetesjournals.org/>
6. Position Statement. Standards of Medical Care in Diabetes. 2014 Diabetes Care. 2014;37; suplemento 1:S14-S80. DOI: 10.2337/dc14-S014. Disponible en: <http://care.diabetesjournals.org/>
7. Ojo de markov Nº 21. Antiagregación y Diabetes. La evolución de las recomendaciones de la ADA. 2010. Disponible en: <http://www.saludcastillayleon.es/portalmedicamento/es/cim-sacyl/numeros-antteriores-ano-2013>
8. Patrono C. El ácido acetilsalicílico continúa siendo objeto de investigación y debate 115 años después de su síntesis. Rev Esp Cardiol. 2013;66:251-4.
9. Antithrombotic Trialists' (ATT) Collaboration. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet. 2009;373:1849–60.
10. Steering Committee of the Physicians' Health Study Research Group. Final report on the aspirin component of the ongoing Physicians' Health Study. N Engl J Med. 1989;321:129–35.
11. Peto R, Gray R, Collins R, Wheatley K, Hennekens C, Jamrozik K, et al. Randomised trial of prophylactic daily aspirin in British male doctors. BMJ. 1988;296:313–6.
12. The Medical Research Council's General Practice Research Framework. Thrombosis prevention trial: randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk. Lancet. 1998;351:233–41.

13. Hansson L, Zanchetti A, Carruthers SG, Dahlof B, Elmfeldt D, Julius S, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. *Lancet*. 1998;351:1755–62.
14. Collaborative Group of the Primary Prevention Project. Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomised trial in general practice. *Lancet*. 2001;357:89–95.
15. Ridker PM, Cook NR, Lee IM, Gordon D, Gaziano JM, Manson JE, et al. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. *N Engl J Med*. 2005;352:1293–304.
16. Belch J, MacCuish A, Campbell I, et al. The Prevention of Progression of Arterial Disease and Diabetes Study Group; Diabetes Registry Group; Royal College of Physicians Edinburgh. The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease. *BMJ* 2008;337:a1840.
17. Ogawa H, Nakayama M, Morimoto T. Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial. *JAMA* 2008;300:2134–2141.
18. Hiatt RW. Aspirin for prevention of cardiovascular events. *BMJ* 2008;337: a 1806
19. Nicolucci A. Aspirin for Primary Prevention of Cardiovascular Events in Diabetes. *JAMA*.2008;300:2180.
20. Chunyu Zhang et al. Aspirin for primary prevention of cardiovascular events in patients with diabetes. A meta-analysis. *Diabetic Research and Clinic Practice*. 2010;87:211-18.
21. A Study of Cardiovascular Events in Diabetes (ASCEND) Study. 2008. <http://www.ctsu.ox.ac.uk/ascend/>
22. De Berardis G, Sacco M, Evangelista V. Aspirin and Simvastatin Combination for Cardiovascular Events Prevention Trials in Diabetes (ACCEPT-D): design of a randomized study of the efficacy of low-dose aspirin in the prevention of cardiovascular events in subjects with diabetes mellitus treated with statins. *Trials* 2007;8:21.
23. Nelson MR, Reid CM, Beilin LJ. Rationale for a trial of low-dose aspirin for the primary prevention of major adverse cardiovascular events and vascular dementia in the elderly. Aspirin in Reducing Events in the Elderly (ASPREE). *Drugs Aging* 2003;20:897–903.
24. Aspirin to Reduce Risk of Initial Vascular Events (ARRIVE) Study. 2008. <http://www.arrivestudy.com/EN/study.cfm>
25. Teramoto T, MD, Shimada K, Chiyama S, et al. Rationale, design, and baseline data of the Japanese Primary Prevention Project (JPPP)—A randomized, open-label, controlled trial of aspirin versus no aspirin in patients with multiple risk factors for vascular events. *Am Heart J* 2010;159:361-9.e4.